Cann Group（CVJ）株式概要キャン・グループ・リミテッドは、その子会社とともに、オーストラリアとヨーロッパで薬用大麻の育種、栽培、製造、販売を行っている。 詳細CVJ ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性1/6配当金0/6報酬株価収益率（ 0.4 x） German市場（ 16.7 x）を下回っています。今年は黒字化を達成 リスク分析意味のある時価総額がありません ( €4M )過去1年間で株主の希薄化は大幅に進んだ 負債は営業キャッシュフローで十分にカバーされていない 高いレベルの非現金収入 +1 さらなるリスクすべてのリスクチェックを見るCVJ Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.000539.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-48m26m2016201920222025202620282031Revenue AU$19.7mEarnings AU$25.7mAdvancedSet Fair ValueView all narrativesCann Group Limited 競合他社Goldline PharmaceuticalSymbol: BSE:544759Market cap: ₹469.9mVasundhara RasayansSymbol: BSE:538634Market cap: ₹495.2mShelter PharmaSymbol: BSE:543963Market cap: ₹505.1mPhong Phu PharmaceuticalSymbol: HNX:PPPMarket cap: ₫160.2b価格と性能株価の高値、安値、推移の概要Cann Group過去の株価現在の株価AU$0.000552週高値AU$0.01352週安値AU$0.0002ベータ0.141ヶ月の変化0%3ヶ月変化150.00%1年変化150.00%3年間の変化-99.43%5年間の変化-99.80%IPOからの変化-99.87%最新ニュースお知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listingお知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australiaお知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.最新情報をもっと見るRecent updatesお知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listingお知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australiaお知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.お知らせ • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct Listingお知らせ • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024お知らせ • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.3m market cap, or US$17.7m).お知らせ • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.お知らせ • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.お知らせ • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listingお知らせ • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€31.6m market cap, or US$34.2m).お知らせ • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.お知らせ • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.お知らせ • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 8.2%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year whereas the company’s share price has fallen by 39% per year.Is New 90 Day High Low • Feb 10New 90-day high: €0.52The company is up 167% from its price of €0.19 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Nov 24New 90-day high: €0.30The company is up 21% from its price of €0.25 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 12New 90-day low: €0.23The company is down 54% from its price of €0.50 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.株主還元CVJDE PharmaceuticalsDE 市場7D0%1.9%-2.6%1Y150.0%21.1%-1.4%株主還元を見る業界別リターン: CVJ過去 1 年間で21.1 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: CVJ過去 1 年間で-1.4 % の収益を上げたGerman市場を上回りました。価格変動Is CVJ's price volatile compared to industry and market?CVJ volatilityCVJ Average Weekly Movement42.3%Pharmaceuticals Industry Average Movement6.4%Market Average Movement5.9%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: CVJの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CVJの 週次ボラティリティ は過去 1 年間で1240%から42%に減少しましたが、依然としてGerman株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/an/awww.canngrouplimited.comキャン・グループ・リミテッドは、その子会社とともに、オーストラリアとヨーロッパで薬用大麻の育種、栽培、製造、販売を行っている。また、ヒトの薬用・研究目的の大麻の研究・栽培のライセンスも取得している。同社は2014年に設立され、オーストラリアのポートメルボルンを拠点としている。もっと見るCann Group Limited 基礎のまとめCann Group の収益と売上を時価総額と比較するとどうか。CVJ 基礎統計学時価総額€3.94m収益（TTM）€8.93m売上高(TTM)€6.86m0.4xPER（株価収益率0.6xP/SレシオCVJ は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CVJ 損益計算書（TTM）収益AU$11.31m売上原価AU$6.15m売上総利益AU$5.16mその他の費用-AU$9.57m収益AU$14.73m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.0091グロス・マージン45.61%純利益率130.29%有利子負債／自己資本比率43.5%CVJ の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 03:56終値2026/06/10 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cann Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cameron BellCanaccord GenuityPaul JenszPAC Partners Securities Pty. Ltd.
お知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia
お知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.
お知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia
お知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Peter Kopanidis was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.
お知らせ • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.
Reported Earnings • Sep 01Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024
お知らせ • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.
Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€16.3m market cap, or US$17.7m).
お知らせ • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.
お知らせ • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.
お知らせ • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Aug 28Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€31.6m market cap, or US$34.2m).
お知らせ • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.
Reported Earnings • Feb 26First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
お知らせ • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.
お知らせ • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 7.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 8.2%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year whereas the company’s share price has fallen by 39% per year.
Is New 90 Day High Low • Feb 10New 90-day high: €0.52The company is up 167% from its price of €0.19 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: €0.30The company is up 21% from its price of €0.25 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 12New 90-day low: €0.23The company is down 54% from its price of €0.50 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
